When considering the primary targets and specific treatment area/format, can anyone here say with confidence that they've invested time in researching biotech opportunities in the EU/US and believe that what IMU possess is by far and away more superior than that of any other listed company with pre-clinical & advanced P1/P2 assets? Are we a global standout (compared to our peers), or are there plenty of 'competitor's' with as avid following that expect that their company will be the one to truly break ground first?
In no way am I trying to be a downer (held strong since 2019) - Just wondering if we've all truly chosen the crowd favourite, or if we've hitched ourselves to the hottest thing going in our (very, very) small domestic market.
Media Thread, page-7162
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $519.7M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.4¢ | 7.0¢ | $1.222M | 16.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 942474 | 7.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 200000 | 2 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
0.000 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.3¢ | 7.0¢ | 6985767 | ||
| Last updated 15.59pm 14/05/2024 ? | |||||
| IMU (ASX) Chart |